<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03095651</url>
  </required_header>
  <id_info>
    <org_study_id>5160-002</org_study_id>
    <secondary_id>MK-5160-002</secondary_id>
    <nct_id>NCT03095651</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)</brief_title>
  <official_title>A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Effect of MK-5160 in Subjects With Type 1 and Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, active- and placebo-controlled, double-blind trial of MK-5160 in
      participants with Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM). This
      is a two-part trial, with three panels per part. T1DM (Part 1) and T2DM (Part 2) participants
      will be given daily fixed doses of MK-5160 in three predefined, increasing doses in each
      panel, or glargine (active comparator). The primary hypothesis of the trial is that at a dose
      with sufficient safety, the mean steady-state maximum level of glucose infusion rate (GIRmax)
      after MK-5160 administration in both T1DM and T2DM participants is between 1.5 and 4.5
      mg/kg/min.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 12, 2017</start_date>
  <completion_date type="Actual">January 30, 2018</completion_date>
  <primary_completion_date type="Actual">January 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event (AE)</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinuing Study Drug Due to an AE</measure>
    <time_frame>Up to 12 days</time_frame>
    <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal Glucose Infusion Rate</measure>
    <time_frame>Up to 24 hours post-dose on Day 12</time_frame>
    <description>Maximal glucose infusion rate required to maintain target glucose levels in a euglycemic clamp setting (GIRmax) at steady state (Day 12) following administration of study drug. In cases where the lower bound of the CI was negative, the lower confidence limit was truncated at zero. In these cases, the confidence intervals are 97.5% CIs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of MK-5160</measure>
    <time_frame>Day 1 clamp: -15 min. (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours following start of injection (FSOI). Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, and 168 hours FSOI.</time_frame>
    <description>Cmax of MK-5160 following multiple dose administration of study drug. Glargine data are presented in the following outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Glargine</measure>
    <time_frame>Day 1 clamp: -15 min. (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI. Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, and 168 hours FSOI.</time_frame>
    <description>Cmax of glargine following multiple dose administration of study drug. MK-5160 data are presented in the preceding outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 12 to Day 1 Accumulation Ratio of Cmax</measure>
    <time_frame>Day 1 clamp: -15 min. (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI. Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, and 168 hours FSOI.</time_frame>
    <description>Day 12 to Day 1 accumulation ratio (AR) of Cmax of MK-5160 and glargine following multiple dose administration of study drug. Geometric mean accumulation ratio = Day 12 Cmax/Day 1 Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady State Plasma Concentration (Css) of MK-5160</measure>
    <time_frame>Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, and 168 hours FSOI.</time_frame>
    <description>Css of MK-5160 is the amount of MK-5160 in a given volume of plasma at the time a &quot;steady state&quot; has been achieved, and rates of MK-5160 administration and MK-5160 elimination are equal. Glargine data are presented in the following outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady State Plasma Concentration (Css) of Glargine</measure>
    <time_frame>Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, and 168 hours FSOI.</time_frame>
    <description>Css of glargine is the amount of glargine in a given volume of plasma at the time a &quot;steady state&quot; has been achieved, and rates of glargine administration and glargine elimination are equal. MK-5160 data are presented in the preceding outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration/Time (AUC0-24) of MK-5160</measure>
    <time_frame>Day 1 clamp: -15 min. (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI. Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI.</time_frame>
    <description>Area Under the Plasma Concentration/Time Curve for MK-5160 from Time 0 to 24 hours (AUC0-24) is a measure of the total amount of MK-5160 in the plasma from the dose administration to 24 hours. Glargine data are presented in the following outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration/Time (AUC0-24) of Glargine</measure>
    <time_frame>Day 1 clamp: -15 min. (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI. Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI.</time_frame>
    <description>AUC0-24 is a measure of the total amount of glargine in the plasma from the dose administration to 24 hours. MK-5160 data are presented in the preceding outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 12 to Day 1 Accumulation Ratio of AUC0-24.</measure>
    <time_frame>Day 1 clamp: -15 min. (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI. Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI.</time_frame>
    <description>Day 12 to Day 1 Accumulation Ratio (AR) of the AUC0-24 of study drug (MK-5160 or glargine). Geometric mean accumulation ratio = Day 12 AUC0-24/Day 1 AUC0-24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Clearance</measure>
    <time_frame>Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, and 168 hours FSOI.</time_frame>
    <description>Plasma Clearance (CL) of study drug is the volume of plasma cleared of study drug per unit time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration</measure>
    <time_frame>Day 1 clamp: -15 min. (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI. Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, and 168 hours FSOI.</time_frame>
    <description>Time to reach the maximum plasma concentration (Tmax) of study drug after the dose is given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life</measure>
    <time_frame>Day 1 clamp: -15 min. (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI. Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, and 168 hours FSOI.</time_frame>
    <description>Apparent Terminal Half-life (t1/2) is the time required for a given MK-5160 concentration in the plasma to decrease by 50%.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>T1DM MK-5160 16 nmol/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T1DM MK-5160 32 nmol/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T1DM MK-5160 64 nmol/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T1DM Glargine 0.4 U/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM MK-5160 16 nmol/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM MK-5160 32 nmol/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM MK-5160 64 nmol/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM Glargine 0.6 U/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MK-5160 16 nmol/kg</intervention_name>
    <description>MK-5160 16 nmol/kg, subcutaneous injection administered daily for 12 days</description>
    <arm_group_label>T1DM MK-5160 16 nmol/kg</arm_group_label>
    <arm_group_label>T2DM MK-5160 16 nmol/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MK-5160 32 nmol/kg</intervention_name>
    <description>MK-5160 32 nmol/kg, subcutaneous injection administered daily for 12 days</description>
    <arm_group_label>T1DM MK-5160 32 nmol/kg</arm_group_label>
    <arm_group_label>T2DM MK-5160 32 nmol/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MK-5160 64 nmol/kg</intervention_name>
    <description>MK-5160 64 nmol/kg, subcutaneous injection administered daily for 12 days</description>
    <arm_group_label>T1DM MK-5160 64 nmol/kg</arm_group_label>
    <arm_group_label>T2DM MK-5160 64 nmol/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Glargine 0.4 U/kg</intervention_name>
    <description>Glargine 0.4 U/kg, subcutaneous injection administered daily for 12 days</description>
    <arm_group_label>T1DM Glargine 0.4 U/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo to Glargine</intervention_name>
    <description>Placebo to glargine, subcutaneous injection administered daily for 12 days</description>
    <arm_group_label>T1DM MK-5160 16 nmol/kg</arm_group_label>
    <arm_group_label>T1DM MK-5160 32 nmol/kg</arm_group_label>
    <arm_group_label>T1DM MK-5160 64 nmol/kg</arm_group_label>
    <arm_group_label>T2DM MK-5160 16 nmol/kg</arm_group_label>
    <arm_group_label>T2DM MK-5160 32 nmol/kg</arm_group_label>
    <arm_group_label>T2DM MK-5160 64 nmol/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo to MK-5160</intervention_name>
    <description>Placebo to MK-5160, subcutaneous injection administered daily for 12 days</description>
    <arm_group_label>T1DM Glargine 0.4 U/kg</arm_group_label>
    <arm_group_label>T2DM Glargine 0.6 U/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextrose</intervention_name>
    <description>20% solution of dextrose; adjusted to maintain the various glycemic levels at 100 mg/dL given as a continuous intravenous infusion for 6-30 hours.</description>
    <arm_group_label>T1DM Glargine 0.4 U/kg</arm_group_label>
    <arm_group_label>T1DM MK-5160 16 nmol/kg</arm_group_label>
    <arm_group_label>T1DM MK-5160 32 nmol/kg</arm_group_label>
    <arm_group_label>T1DM MK-5160 64 nmol/kg</arm_group_label>
    <arm_group_label>T2DM Glargine 0.6 U/kg</arm_group_label>
    <arm_group_label>T2DM MK-5160 16 nmol/kg</arm_group_label>
    <arm_group_label>T2DM MK-5160 32 nmol/kg</arm_group_label>
    <arm_group_label>T2DM MK-5160 64 nmol/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Glargine 0.6 U/kg</intervention_name>
    <description>Glargine 0.6 U/kg, subcutaneous injection administered daily for 12 days</description>
    <arm_group_label>T2DM Glargine 0.6 U/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For Part 1 (T1DM):

          -  Be male, or female of non-childbearing potential. A female of non-childbearing
             potential defined as a female who is postmenopausal without menses for at least 1 year
             and has a follicle stimulating hormone (FSH) value in the postmenopausal range upon
             pretrial (screening) evaluation OR a female who is status post hysterectomy,
             oophorectomy or tubal ligation.

          -  Be judged to be in good health

          -  Have a diagnosis of T1DM as defined by standard diagnostic criteria for ≥12 months at
             time study participation

          -  Be on stable doses of basal insulin over the 2-week period prior to screening and over
             the 2 weeks prior to dosing.

          -  Have a total daily insulin requirement (basal plus prandial) of ≤ 1.2 units/kg.

          -  Have a hemoglobin A1C (HbA1c) ≤10% at the time of study participation.

          -  Have a Body Mass Index (BMI) ≥18.5 kg/m^2 and ≤ 32 kg/m^2. BMI = mass (kg)/height
             (m)^2

          -  Be a non-smoker or smoker who uses no more than 5 cigarettes or equivalent (e.g.,
             e-cigarettes) per day over the prior 3 month period also may be enrolled (at the
             discretion of the investigator). The subject must agree to follow the smoking
             restrictions defined by the clinical research unit (CRU).

          -  For Part 2 (T2DM):

          -  Be male, or female of non-childbearing potential. A female of non-childbearing
             potential defined as a female who is postmenopausal without menses for at least 1 year
             and has a FSH value in the postmenopausal range upon pretrial (screening) evaluation
             OR a female who is status post hysterectomy, oophorectomy or tubal ligation.

          -  Be judged to be in good health

          -  Have a diagnosis of T2DM as defined by standard diagnostic criteria for ≥12 month at
             time of study participation.

          -  T2DM participants are not required to have been on insulin. If on insulin,
             participants should have a total daily insulin requirement of ≤ 1.2 units/kg, and have
             been on stable doses of basal insulin over the 2-week period prior to screening and
             over the 2 weeks prior to dosing.

          -  Meet one of the following criteria:

               1. Be on no anti-hyperglycemic agent (AHA), or on metformin monotherapy or metformin
                  plus a dipeptidyl peptidase-4 (DPP4) inhibitor at stable doses for at least 8
                  weeks prior to screening, with a screening HbA1C ≥7.0 and ≤10.0%.

               2. Be on either a sulfonylurea (e.g. glyburide) or an alpha-glucosidase inhibitors
                  (e.g., acarbose) alone or in combination with metformin at stable doses for at
                  least 8 weeks prior to screening with a screening HbA1C ≥7.0 and ≤9.0%.
                  Participants on these medications must be willing to stop the sulfonylurea or
                  alpha-glucosidase inhibitor after screening once they qualify for study
                  participation.

          -  Have a BMI ≥18.5 kg/m^2 and ≤ 35.0 kg/m^2 BMI = mass (kg)/height (m)^2

          -  May be on selected standard medications for T2DM, including alpha-glucosidase
             inhibitors (e.g., acarbose), sulfonylureas (e.g. glyburide), DPP-4 inhibitors, and
             metformin. Participants on alpha-glucosidase inhibitors and/or sulfonylureas must stop
             these medications for at least one week prior to checking into the site and for the
             duration of the trial through the last dose of MK-5160/glargine. Participants on
             metformin or DPP-4 inhibitors may continue on their home dose for the duration of the
             trial. Participants on SGLT2 inhibitors (gliflozins), thiazolidinediones or GLP-1
             agonists are excluded.

          -  Be a nonsmoker or smoker who uses no greater than 5 cigarettes or equivalent (e.g.,
             e-cigarettes) daily over the prior 3 month period. Participants must agree to follow
             the smoking restrictions defined by the CRU.

        Exclusion Criteria:

          -  For Part 1 (T1DM) and Part 2 (T2DM):

          -  Is under the age of legal consent

          -  Is mentally or legally incapacitated, has significant emotional problems at the time
             of pretrial (screening) visit or expected during the conduct of the trial or has a
             history of clinically significant psychiatric disorder of the last 5 years.
             Participants who have had situational depression may be enrolled in the trial at the
             discretion of the investigator.

          -  Has a history of clinically significant endocrine (excluding diabetes mellitus),
             gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal,
             respiratory, genitourinary or major neurological (including stroke and chronic
             seizures) abnormalities or diseases. Participants with a history of uncomplicated
             kidney stones, as defined as spontaneous passage and no recurrence in the last 5
             years, or childhood asthma may be enrolled in the trial at the discretion of the
             investigator.

          -  Has a history of cancer (malignancy) Exceptions: (1) Participants with adequately
             treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix may
             participate in the trial; (2) Participants with other malignancies which have been
             successfully treated ≥10 years prior to the pretrial visit

          -  Has a history of significant multiple and/or severe allergies (e.g. food, drug, latex
             allergy), or has had an anaphylactic reaction or significant intolerability (i.e.
             systemic allergic reaction) to prescription or non-prescription drugs or food.

          -  Is positive for hepatitis B surface antigen, hepatitis C antibodies or HIV at
             Screening.

          -  Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4
             weeks prior to the pretrial visit.

          -  Has participated in another investigational trial within 4 weeks (or 5 half-lives),
             whichever is greater, prior to the pretrial visit.

          -  Is unable to refrain from or anticipates the use of any medication, including
             prescription and non-prescription drugs or herbal remedies beginning approximately 2
             weeks (or 5 half-lives) prior to administration of the initial dose of trial drug,
             throughout the trial (including washout intervals between treatment periods), until
             the post-trial visit. Certain medications, such as antihypertensives and aspirin, are
             permitted.

          -  Consumes greater than 3 glasses of alcoholic beverages (1 glass is approximately
             equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or distilled spirits
             [29.5 mL/1 ounce]) per day.

          -  Consumes excessive amounts, defined as greater than 6 servings (1 serving is
             approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy-drinks,
             or other caffeinated beverages per day.

          -  Is a regular user of cannabis or any illicit drugs, or has a history of drug
             (including alcohol) abuse within approximately 6 months.

          -  Has the diagnosis of hypoglycemia unawareness, or has had one or more severe
             hypoglycemic episodes associated with hypoglycemic seizures, comas or unconsciousness
             within 6 months prior to dosing.

          -  Has used systemic (intravenous, oral, inhaled) glucocorticoids within 3 months of
             screening or is anticipated to require treatment with systemic glucocorticoids during
             study participation.

          -  Has other major medical problems requiring medication (i.e., history of myocardial
             infarction, hypercholesterolemia). Participants on aspirin as prophylaxis may be
             enrolled, provided there is no history of MI or other thromboembolic event, or a
             history of coronary atherosclerosis.

          -  Has a known history of celiac disease or significant food allergy, at the discretion
             of the Investigator and Sponsor.

          -  Has a history of hypersensitivity to pharmacologic insulins or to any of the inactive
             ingredients in regular human insulin, or to any E.coli-derived drug product.

          -  For Part 1 (T1DM) Only:

          -  Has a history of diabetic ketoacidosis in the last 12 months.

          -  For Part 2 (T2DM) Only

          -  Has been treated with a sodium/glucose cotransporter 2 (SGLT2) inhibitor (gliflozins),
             thiazolidinedione or Glucagon-like peptide-1 (GLP-1) receptor agonist within the past
             three months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ProSciento Inc. ( Site 0001)</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 27, 2017</study_first_submitted>
  <study_first_submitted_qc>March 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2017</study_first_posted>
  <results_first_submitted>December 14, 2018</results_first_submitted>
  <results_first_submitted_qc>March 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 1, 2019</results_first_posted>
  <last_update_submitted>March 29, 2019</last_update_submitted>
  <last_update_submitted_qc>March 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT03095651/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>No participants were randomized to the T1DM (Type 1 Diabetes Mellitus) MK-5160 64 nmol/kg arm or the T2DM (Type 2 Diabetes Mellitus) MK-5160 16 nmol/kg arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>T1DM MK-5160 16 Nmol/kg</title>
          <description>Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="P2">
          <title>T1DM MK-5160 32 Nmol/kg</title>
          <description>Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="P3">
          <title>T1DM MK-5160 64 Nmol/kg</title>
          <description>Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="P4">
          <title>T1DM Glargine 0.4 U/kg</title>
          <description>Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="P5">
          <title>T2DM MK-5160 16 Nmol/kg</title>
          <description>Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="P6">
          <title>T2DM MK-5160 32 Nmol/kg</title>
          <description>Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="P7">
          <title>T2DM MK-5160 64 Nmol/kg</title>
          <description>Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="P8">
          <title>T2DM Glargine 0.6 U/kg</title>
          <description>Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No participants were randomized to the T1DM MK-5160 64 nmol/kg arm or the T2DM MK-5160 16 nmol/kg arm.</population>
      <group_list>
        <group group_id="B1">
          <title>T1DM MK-5160 16 Nmol/kg</title>
          <description>Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="B2">
          <title>T1DM MK-5160 32 Nmol/kg</title>
          <description>Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="B3">
          <title>T1DM MK-5160 64 Nmol/kg</title>
          <description>Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="B4">
          <title>T1DM Glargine 0.4 U/kg</title>
          <description>Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="B5">
          <title>T2DM MK-5160 16 Nmol/kg</title>
          <description>Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="B6">
          <title>T2DM MK-5160 32 Nmol/kg</title>
          <description>Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="B7">
          <title>T2DM MK-5160 64 Nmol/kg</title>
          <description>Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="B8">
          <title>T2DM Glargine 0.6 U/kg</title>
          <description>Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="0"/>
            <count group_id="B6" value="7"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="4"/>
            <count group_id="B9" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Between 18 and 64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>From 65 to 84 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing an Adverse Event (AE)</title>
        <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
        <time_frame>Up to 33 days</time_frame>
        <population>All participants who received at least one dose of study drug. No participants were randomized to the T1DM MK-5160 64 nmol/kg arm or the T2DM MK-5160 16 nmol/kg arm.</population>
        <group_list>
          <group group_id="O1">
            <title>T1DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>T1DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>T1DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O4">
            <title>T1DM Glargine 0.4 U/kg</title>
            <description>Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O5">
            <title>T2DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O6">
            <title>T2DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O7">
            <title>T2DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O8">
            <title>T2DM Glargine 0.6 U/kg</title>
            <description>Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing an Adverse Event (AE)</title>
          <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
          <population>All participants who received at least one dose of study drug. No participants were randomized to the T1DM MK-5160 64 nmol/kg arm or the T2DM MK-5160 16 nmol/kg arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Discontinuing Study Drug Due to an AE</title>
        <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
        <time_frame>Up to 12 days</time_frame>
        <population>All participants who received at least one dose of study drug. No participants were randomized to the T1DM MK-5160 64 nmol/kg arm or the T2DM MK-5160 16 nmol/kg arm.</population>
        <group_list>
          <group group_id="O1">
            <title>T1DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>T1DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>T1DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O4">
            <title>T1DM Glargine 0.4 U/kg</title>
            <description>Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O5">
            <title>T2DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O6">
            <title>T2DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O7">
            <title>T2DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O8">
            <title>T2DM Glargine 0.6 U/kg</title>
            <description>Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Discontinuing Study Drug Due to an AE</title>
          <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
          <population>All participants who received at least one dose of study drug. No participants were randomized to the T1DM MK-5160 64 nmol/kg arm or the T2DM MK-5160 16 nmol/kg arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximal Glucose Infusion Rate</title>
        <description>Maximal glucose infusion rate required to maintain target glucose levels in a euglycemic clamp setting (GIRmax) at steady state (Day 12) following administration of study drug. In cases where the lower bound of the CI was negative, the lower confidence limit was truncated at zero. In these cases, the confidence intervals are 97.5% CIs.</description>
        <time_frame>Up to 24 hours post-dose on Day 12</time_frame>
        <population>All participants that received study drug, had no major protocol violations, and had GIRmax values available on Day 12. No participants were randomized to the T1DM MK-5160 64 nmol/kg arm or the T2DM MK-5160 16 nmol/kg arm.</population>
        <group_list>
          <group group_id="O1">
            <title>T1DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>T1DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>T1DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O4">
            <title>T1DM Glargine 0.4 U/kg</title>
            <description>Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O5">
            <title>T2DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O6">
            <title>T2DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O7">
            <title>T2DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O8">
            <title>T2DM Glargine 0.6 U/kg</title>
            <description>Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Glucose Infusion Rate</title>
          <description>Maximal glucose infusion rate required to maintain target glucose levels in a euglycemic clamp setting (GIRmax) at steady state (Day 12) following administration of study drug. In cases where the lower bound of the CI was negative, the lower confidence limit was truncated at zero. In these cases, the confidence intervals are 97.5% CIs.</description>
          <population>All participants that received study drug, had no major protocol violations, and had GIRmax values available on Day 12. No participants were randomized to the T1DM MK-5160 64 nmol/kg arm or the T2DM MK-5160 16 nmol/kg arm.</population>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" lower_limit="1.04" upper_limit="3.25"/>
                    <measurement group_id="O2" value="2.86" lower_limit="1.80" upper_limit="3.92"/>
                    <measurement group_id="O4" value="2.56" lower_limit="1.26" upper_limit="3.86"/>
                    <measurement group_id="O6" value="1.98" lower_limit="1.03" upper_limit="2.93"/>
                    <measurement group_id="O7" value="2.15" lower_limit="1.15" upper_limit="3.14"/>
                    <measurement group_id="O8" value="3.25" lower_limit="2.03" upper_limit="4.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of MK-5160</title>
        <description>Cmax of MK-5160 following multiple dose administration of study drug. Glargine data are presented in the following outcome measure.</description>
        <time_frame>Day 1 clamp: -15 min. (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours following start of injection (FSOI). Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, and 168 hours FSOI.</time_frame>
        <population>All participants that received MK-5160, had no major protocol violations, and had Cmax values available on Day 1 and Day 12. No participants were randomized to the T1DM MK-5160 64 nmol/kg or T2DM MK-5160 16 nmol/kg arms. One participant in the T2DM MK-5160 32 nmol/kg arm withdrew consent after receiving a single dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>T1DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>T1DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>T1DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O4">
            <title>T1DM Glargine 0.4 U/kg</title>
            <description>Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O5">
            <title>T2DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O6">
            <title>T2DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O7">
            <title>T2DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O8">
            <title>T2DM Glargine 0.6 U/kg</title>
            <description>Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of MK-5160</title>
          <description>Cmax of MK-5160 following multiple dose administration of study drug. Glargine data are presented in the following outcome measure.</description>
          <population>All participants that received MK-5160, had no major protocol violations, and had Cmax values available on Day 1 and Day 12. No participants were randomized to the T1DM MK-5160 64 nmol/kg or T2DM MK-5160 16 nmol/kg arms. One participant in the T2DM MK-5160 32 nmol/kg arm withdrew consent after receiving a single dose of study drug.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" lower_limit="0.59" upper_limit="0.97"/>
                    <measurement group_id="O2" value="1.58" lower_limit="0.99" upper_limit="2.53"/>
                    <measurement group_id="O6" value="1.33" lower_limit="0.97" upper_limit="1.82"/>
                    <measurement group_id="O7" value="1.91" lower_limit="1.22" upper_limit="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" lower_limit="1.75" upper_limit="3.10"/>
                    <measurement group_id="O2" value="5.38" lower_limit="3.33" upper_limit="8.69"/>
                    <measurement group_id="O6" value="3.85" lower_limit="2.94" upper_limit="5.05"/>
                    <measurement group_id="O7" value="9.03" lower_limit="7.73" upper_limit="10.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of Glargine</title>
        <description>Cmax of glargine following multiple dose administration of study drug. MK-5160 data are presented in the preceding outcome measure.</description>
        <time_frame>Day 1 clamp: -15 min. (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI. Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, and 168 hours FSOI.</time_frame>
        <population>All participants that received glargine, had no major protocol violations, and had Cmax values available on Day 1 and Day 12.</population>
        <group_list>
          <group group_id="O1">
            <title>T1DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>T1DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>T1DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O4">
            <title>T1DM Glargine 0.4 U/kg</title>
            <description>Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O5">
            <title>T2DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O6">
            <title>T2DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O7">
            <title>T2DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O8">
            <title>T2DM Glargine 0.6 U/kg</title>
            <description>Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Glargine</title>
          <description>Cmax of glargine following multiple dose administration of study drug. MK-5160 data are presented in the preceding outcome measure.</description>
          <population>All participants that received glargine, had no major protocol violations, and had Cmax values available on Day 1 and Day 12.</population>
          <units>pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="17.26" lower_limit="13.12" upper_limit="22.70"/>
                    <measurement group_id="O8" value="18.97" lower_limit="5.29" upper_limit="68.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="20.28" lower_limit="10.74" upper_limit="38.28"/>
                    <measurement group_id="O8" value="34.18" lower_limit="12.73" upper_limit="91.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 12 to Day 1 Accumulation Ratio of Cmax</title>
        <description>Day 12 to Day 1 accumulation ratio (AR) of Cmax of MK-5160 and glargine following multiple dose administration of study drug. Geometric mean accumulation ratio = Day 12 Cmax/Day 1 Cmax.</description>
        <time_frame>Day 1 clamp: -15 min. (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI. Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, and 168 hours FSOI.</time_frame>
        <population>Participants with Cmax measurements on Day 1 and Day 12. No participants were randomized to the T1DM MK-5160 64 nmol/kg arm or the T2DM MK-5160 16 nmol/kg arm.</population>
        <group_list>
          <group group_id="O1">
            <title>T1DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>T1DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>T1DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O4">
            <title>T1DM Glargine 0.4 U/kg</title>
            <description>Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O5">
            <title>T2DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O6">
            <title>T2DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O7">
            <title>T2DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O8">
            <title>T2DM Glargine 0.6 U/kg</title>
            <description>Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 12 to Day 1 Accumulation Ratio of Cmax</title>
          <description>Day 12 to Day 1 accumulation ratio (AR) of Cmax of MK-5160 and glargine following multiple dose administration of study drug. Geometric mean accumulation ratio = Day 12 Cmax/Day 1 Cmax.</description>
          <population>Participants with Cmax measurements on Day 1 and Day 12. No participants were randomized to the T1DM MK-5160 64 nmol/kg arm or the T2DM MK-5160 16 nmol/kg arm.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.08" lower_limit="2.37" upper_limit="4.00"/>
                    <measurement group_id="O2" value="3.40" lower_limit="2.11" upper_limit="5.48"/>
                    <measurement group_id="O4" value="1.17" lower_limit="0.80" upper_limit="1.74"/>
                    <measurement group_id="O6" value="2.89" lower_limit="2.13" upper_limit="3.93"/>
                    <measurement group_id="O7" value="4.72" lower_limit="3.46" upper_limit="6.44"/>
                    <measurement group_id="O8" value="1.80" lower_limit="0.65" upper_limit="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steady State Plasma Concentration (Css) of MK-5160</title>
        <description>Css of MK-5160 is the amount of MK-5160 in a given volume of plasma at the time a &quot;steady state&quot; has been achieved, and rates of MK-5160 administration and MK-5160 elimination are equal. Glargine data are presented in the following outcome measure.</description>
        <time_frame>Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, and 168 hours FSOI.</time_frame>
        <population>All participants that received MK-5160, had no major protocol violations, and had Css values available on Day 12. No participants were randomized to the T1DM MK-5160 64 nmol/kg arm or the T2DM MK-5160 16 nmol/kg arm.</population>
        <group_list>
          <group group_id="O1">
            <title>T1DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>T1DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>T1DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O4">
            <title>T1DM Glargine 0.4 U/kg</title>
            <description>Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O5">
            <title>T2DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O6">
            <title>T2DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O7">
            <title>T2DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O8">
            <title>T2DM Glargine 0.6 U/kg</title>
            <description>Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
        </group_list>
        <measure>
          <title>Steady State Plasma Concentration (Css) of MK-5160</title>
          <description>Css of MK-5160 is the amount of MK-5160 in a given volume of plasma at the time a &quot;steady state&quot; has been achieved, and rates of MK-5160 administration and MK-5160 elimination are equal. Glargine data are presented in the following outcome measure.</description>
          <population>All participants that received MK-5160, had no major protocol violations, and had Css values available on Day 12. No participants were randomized to the T1DM MK-5160 64 nmol/kg arm or the T2DM MK-5160 16 nmol/kg arm.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" lower_limit="1.32" upper_limit="2.42"/>
                    <measurement group_id="O2" value="4.40" lower_limit="2.55" upper_limit="7.57"/>
                    <measurement group_id="O6" value="2.64" lower_limit="1.95" upper_limit="3.56"/>
                    <measurement group_id="O7" value="6.15" lower_limit="5.73" upper_limit="6.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steady State Plasma Concentration (Css) of Glargine</title>
        <description>Css of glargine is the amount of glargine in a given volume of plasma at the time a &quot;steady state&quot; has been achieved, and rates of glargine administration and glargine elimination are equal. MK-5160 data are presented in the preceding outcome measure.</description>
        <time_frame>Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, and 168 hours FSOI.</time_frame>
        <population>All participants that received glargine, had no major protocol violations, and had Css values available on Day 12.</population>
        <group_list>
          <group group_id="O1">
            <title>T1DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>T1DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>T1DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O4">
            <title>T1DM Glargine 0.4 U/kg</title>
            <description>Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O5">
            <title>T2DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O6">
            <title>T2DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O7">
            <title>T2DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O8">
            <title>T2DM Glargine 0.6 U/kg</title>
            <description>Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
        </group_list>
        <measure>
          <title>Steady State Plasma Concentration (Css) of Glargine</title>
          <description>Css of glargine is the amount of glargine in a given volume of plasma at the time a &quot;steady state&quot; has been achieved, and rates of glargine administration and glargine elimination are equal. MK-5160 data are presented in the preceding outcome measure.</description>
          <population>All participants that received glargine, had no major protocol violations, and had Css values available on Day 12.</population>
          <units>pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="9.99" lower_limit="3.32" upper_limit="30.12"/>
                    <measurement group_id="O8" value="14.72" lower_limit="3.45" upper_limit="62.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration/Time (AUC0-24) of MK-5160</title>
        <description>Area Under the Plasma Concentration/Time Curve for MK-5160 from Time 0 to 24 hours (AUC0-24) is a measure of the total amount of MK-5160 in the plasma from the dose administration to 24 hours. Glargine data are presented in the following outcome measure.</description>
        <time_frame>Day 1 clamp: -15 min. (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI. Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI.</time_frame>
        <population>All participants that received MK-5160, had no major protocol violations, and had AUC0-24 values available on Day 1 and Day 12. No participants were randomized to the T1DM MK-5160 64 nmol/kg or T2DM MK-5160 16 nmol/kg arms. One participant in the T2DM MK-5160 32 nmol/kg arm withdrew consent after receiving a single dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>T1DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>T1DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>T1DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O4">
            <title>T1DM Glargine 0.4 U/kg</title>
            <description>Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O5">
            <title>T2DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O6">
            <title>T2DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O7">
            <title>T2DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O8">
            <title>T2DM Glargine 0.6 U/kg</title>
            <description>Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration/Time (AUC0-24) of MK-5160</title>
          <description>Area Under the Plasma Concentration/Time Curve for MK-5160 from Time 0 to 24 hours (AUC0-24) is a measure of the total amount of MK-5160 in the plasma from the dose administration to 24 hours. Glargine data are presented in the following outcome measure.</description>
          <population>All participants that received MK-5160, had no major protocol violations, and had AUC0-24 values available on Day 1 and Day 12. No participants were randomized to the T1DM MK-5160 64 nmol/kg or T2DM MK-5160 16 nmol/kg arms. One participant in the T2DM MK-5160 32 nmol/kg arm withdrew consent after receiving a single dose of study drug.</population>
          <units>hr*nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.79" lower_limit="7.80" upper_limit="12.29"/>
                    <measurement group_id="O2" value="26.39" lower_limit="15.21" upper_limit="45.76"/>
                    <measurement group_id="O6" value="17.44" lower_limit="10.88" upper_limit="27.94"/>
                    <measurement group_id="O7" value="25.32" lower_limit="16.61" upper_limit="38.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.90" lower_limit="31.64" upper_limit="58.17"/>
                    <measurement group_id="O2" value="105.5" lower_limit="61.30" upper_limit="181.7"/>
                    <measurement group_id="O6" value="63.29" lower_limit="46.83" upper_limit="85.52"/>
                    <measurement group_id="O7" value="147.7" lower_limit="137.5" upper_limit="158.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration/Time (AUC0-24) of Glargine</title>
        <description>AUC0-24 is a measure of the total amount of glargine in the plasma from the dose administration to 24 hours. MK-5160 data are presented in the preceding outcome measure.</description>
        <time_frame>Day 1 clamp: -15 min. (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI. Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI.</time_frame>
        <population>All participants that received glargine, had no major protocol violations, and had AUC0-24 values available on Day 1 and Day 12.</population>
        <group_list>
          <group group_id="O1">
            <title>T1DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>T1DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>T1DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O4">
            <title>T1DM Glargine 0.4 U/kg</title>
            <description>Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O5">
            <title>T2DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O6">
            <title>T2DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O7">
            <title>T2DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O8">
            <title>T2DM Glargine 0.6 U/kg</title>
            <description>Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration/Time (AUC0-24) of Glargine</title>
          <description>AUC0-24 is a measure of the total amount of glargine in the plasma from the dose administration to 24 hours. MK-5160 data are presented in the preceding outcome measure.</description>
          <population>All participants that received glargine, had no major protocol violations, and had AUC0-24 values available on Day 1 and Day 12.</population>
          <units>hr*pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="193.6" lower_limit="96.81" upper_limit="387.2"/>
                    <measurement group_id="O8" value="149.6" lower_limit="13.94" upper_limit="1605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="239.8" lower_limit="79.57" upper_limit="722.9"/>
                    <measurement group_id="O8" value="353.3" lower_limit="82.90" upper_limit="1506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 12 to Day 1 Accumulation Ratio of AUC0-24.</title>
        <description>Day 12 to Day 1 Accumulation Ratio (AR) of the AUC0-24 of study drug (MK-5160 or glargine). Geometric mean accumulation ratio = Day 12 AUC0-24/Day 1 AUC0-24</description>
        <time_frame>Day 1 clamp: -15 min. (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI. Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI.</time_frame>
        <population>Participants with AUC0-24 measurements on Day 1 and Day 12. No participants were randomized to the T1DM MK-5160 64 nmol/kg arm or the T2DM MK-5160 16 nmol/kg arm.</population>
        <group_list>
          <group group_id="O1">
            <title>T1DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>T1DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>T1DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O4">
            <title>T1DM Glargine 0.4 U/kg</title>
            <description>Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O5">
            <title>T2DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O6">
            <title>T2DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O7">
            <title>T2DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O8">
            <title>T2DM Glargine 0.6 U/kg</title>
            <description>Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 12 to Day 1 Accumulation Ratio of AUC0-24.</title>
          <description>Day 12 to Day 1 Accumulation Ratio (AR) of the AUC0-24 of study drug (MK-5160 or glargine). Geometric mean accumulation ratio = Day 12 AUC0-24/Day 1 AUC0-24</description>
          <population>Participants with AUC0-24 measurements on Day 1 and Day 12. No participants were randomized to the T1DM MK-5160 64 nmol/kg arm or the T2DM MK-5160 16 nmol/kg arm.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38" lower_limit="3.34" upper_limit="5.74"/>
                    <measurement group_id="O2" value="4.00" lower_limit="2.30" upper_limit="6.94"/>
                    <measurement group_id="O4" value="1.24" lower_limit="0.77" upper_limit="1.99"/>
                    <measurement group_id="O6" value="3.63" lower_limit="2.37" upper_limit="5.56"/>
                    <measurement group_id="O7" value="5.83" lower_limit="4.30" upper_limit="7.91"/>
                    <measurement group_id="O8" value="2.36" lower_limit="0.41" upper_limit="13.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Clearance</title>
        <description>Plasma Clearance (CL) of study drug is the volume of plasma cleared of study drug per unit time.</description>
        <time_frame>Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, and 168 hours FSOI.</time_frame>
        <population>All participants that received study drug, had no major protocol violations, and had CL values available on Day 12. No participants were randomized to the T1DM MK-5160 64 nmol/kg arm or the T2DM MK-5160 16 nmol/kg arm.</population>
        <group_list>
          <group group_id="O1">
            <title>T1DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>T1DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>T1DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O4">
            <title>T1DM Glargine 0.4 U/kg</title>
            <description>Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O5">
            <title>T2DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O6">
            <title>T2DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O7">
            <title>T2DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O8">
            <title>T2DM Glargine 0.6 U/kg</title>
            <description>Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Clearance</title>
          <description>Plasma Clearance (CL) of study drug is the volume of plasma cleared of study drug per unit time.</description>
          <population>All participants that received study drug, had no major protocol violations, and had CL values available on Day 12. No participants were randomized to the T1DM MK-5160 64 nmol/kg arm or the T2DM MK-5160 16 nmol/kg arm.</population>
          <units>L/hr/kg</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" lower_limit="0.28" upper_limit="0.51"/>
                    <measurement group_id="O2" value="0.30" lower_limit="0.18" upper_limit="0.52"/>
                    <measurement group_id="O4" value="10.01" lower_limit="3.32" upper_limit="30.16"/>
                    <measurement group_id="O6" value="0.51" lower_limit="0.37" upper_limit="0.68"/>
                    <measurement group_id="O7" value="0.43" lower_limit="0.40" upper_limit="0.47"/>
                    <measurement group_id="O8" value="10.19" lower_limit="2.39" upper_limit="43.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration</title>
        <description>Time to reach the maximum plasma concentration (Tmax) of study drug after the dose is given.</description>
        <time_frame>Day 1 clamp: -15 min. (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI. Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, and 168 hours FSOI.</time_frame>
        <population>All participants that received study drug, had no major protocol violations, and had Tmax values available on Day 1 and Day 12. No participants were randomized to the T1DM MK-5160 64 nmol/kg arm or the T2DM MK-5160 16 nmol/kg arm.</population>
        <group_list>
          <group group_id="O1">
            <title>T1DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>T1DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>T1DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O4">
            <title>T1DM Glargine 0.4 U/kg</title>
            <description>Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O5">
            <title>T2DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O6">
            <title>T2DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O7">
            <title>T2DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O8">
            <title>T2DM Glargine 0.6 U/kg</title>
            <description>Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration</title>
          <description>Time to reach the maximum plasma concentration (Tmax) of study drug after the dose is given.</description>
          <population>All participants that received study drug, had no major protocol violations, and had Tmax values available on Day 1 and Day 12. No participants were randomized to the T1DM MK-5160 64 nmol/kg arm or the T2DM MK-5160 16 nmol/kg arm.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.50" upper_limit="23.92"/>
                    <measurement group_id="O2" value="0.75" lower_limit="0.50" upper_limit="23.92"/>
                    <measurement group_id="O4" value="3.49" lower_limit="0.50" upper_limit="12.00"/>
                    <measurement group_id="O6" value="1.00" lower_limit="1.00" upper_limit="23.92"/>
                    <measurement group_id="O7" value="1.00" lower_limit="0.98" upper_limit="23.92"/>
                    <measurement group_id="O8" value="1.49" lower_limit="0.98" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O4" value="1.50" lower_limit="0.50" upper_limit="1.98"/>
                    <measurement group_id="O6" value="1.00" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O7" value="1.00" lower_limit="0.50" upper_limit="6.00"/>
                    <measurement group_id="O8" value="0.98" lower_limit="0.50" upper_limit="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Half-life</title>
        <description>Apparent Terminal Half-life (t1/2) is the time required for a given MK-5160 concentration in the plasma to decrease by 50%.</description>
        <time_frame>Day 1 clamp: -15 min. (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours FSOI. Day 12: -15 min (predose), 10, 30 min., 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, and 168 hours FSOI.</time_frame>
        <population>All participants that received MK-5160, had no major protocol violations, and had t1/2 values available on Day 1 and Day 12. t1/2 was not calculated for the Glargine 0.4 U/kg and 0.6 U/kg arms. No participants were randomized to the T1DM MK-5160 64 nmol/kg or T2DM MK-5160 16 nmol/kg arms.</population>
        <group_list>
          <group group_id="O1">
            <title>T1DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>T1DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>T1DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O4">
            <title>T1DM Glargine 0.4 U/kg</title>
            <description>Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O5">
            <title>T2DM MK-5160 16 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O6">
            <title>T2DM MK-5160 32 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O7">
            <title>T2DM MK-5160 64 Nmol/kg</title>
            <description>Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
          <group group_id="O8">
            <title>T2DM Glargine 0.6 U/kg</title>
            <description>Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life</title>
          <description>Apparent Terminal Half-life (t1/2) is the time required for a given MK-5160 concentration in the plasma to decrease by 50%.</description>
          <population>All participants that received MK-5160, had no major protocol violations, and had t1/2 values available on Day 1 and Day 12. t1/2 was not calculated for the Glargine 0.4 U/kg and 0.6 U/kg arms. No participants were randomized to the T1DM MK-5160 64 nmol/kg or T2DM MK-5160 16 nmol/kg arms.</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.01" spread="59.84"/>
                    <measurement group_id="O2" value="21.69" spread="27.70"/>
                    <measurement group_id="O6" value="13.10" spread="36.05"/>
                    <measurement group_id="O7" value="14.47" spread="16.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 33 days</time_frame>
      <desc>All participants who received at least one dose of study drug. No participants were randomized to the T1DM MK-5160 64 nmol/kg arm or the T2DM MK-5160 16 nmol/kg arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>T1DM MK-5160 16 Nmol/kg</title>
          <description>Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="E2">
          <title>T1DM MK-5160 32 Nmol/kg</title>
          <description>Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="E3">
          <title>T1DM MK-5160 64 Nmol/kg</title>
          <description>Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="E4">
          <title>T1DM Glargine 0.4 U/kg</title>
          <description>Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="E5">
          <title>T2DM MK-5160 16 Nmol/kg</title>
          <description>Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="E6">
          <title>T2DM MK-5160 32 Nmol/kg</title>
          <description>Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="E7">
          <title>T2DM MK-5160 64 Nmol/kg</title>
          <description>Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
        <group group_id="E8">
          <title>T2DM Glargine 0.6 U/kg</title>
          <description>Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="8" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="6" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="68" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="54" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="38" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pseuodohypoglycaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="13" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

